UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549



FORM
10-K

Amendment
No. 2



|[x] |  | ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|--- |  | ----------------------------------------------------------------------------------------



For
the fiscal year ended August 31, 2015



|[  ] |  | TRANSITION
    REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|---- |  | --------------------------------------------------------------------------------------



Commission
file number: 000-52445



PETLIFE
PHARMACEUTICALS, INC,

(FORMERLY
CLEAR TV VENTURES, INC.)

(Name
of registrant as specified in its charter)



|Nevada                                                      |  | 33-1133537             
|----------------------------------------------------------- |  | -----------------------
|(State
    or other jurisdiction of                         |  | (I.R.S.
    Employer   
|incorporation
    or organization)                          |  | Identification
    No.)
|                                                            |  |                        
|433
        N. Camden Dr.
        Beverly
        Hills, CA |  | 90210                  
|(Address
    of principal executive offices)                |  | (Zip
    Code)         



(310)
279-5152

(Registrant’s
telephone number, including area code)



Securities
registered pursuant to Section 12(b) of the Act: None



Securities
registered pursuant to Section 12(g) of the Act:

Common
Stock, $0.001 par value



Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes
[  ] No [x]



Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.
Yes [  ] No [x]



Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [x] No [  ]



Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes [x] No [  ]



Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. [  ]



Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See definition of “accelerated filer”, “large accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.



|Large
    accelerated filer [  ] |  | Accelerated
    filer [  ] |  | Non-accelerated
    filer [  ] |  | Smaller
    reporting company [x]
|-------------------------------- |  | -------------------------- |  | ------------------------------ |  | ---------------------------------



Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [x]



The
aggregate market value of the common stock of the registrant held by non-affiliates as of November 28, 2014 the last business
day of the registrant’s most recently completed first fiscal quarter based on the closing sale prices of the registrant’s
common stock on that date as reported on the OTCQB maintained by OTC Markets Group, Inc. was $15,338,480. For purposes of this
computation, all officers, directors, and 5 percent beneficial owners of the registrant are deemed to be affiliates. Such determination
should not be deemed an admission that such directors, officers, or 5 percent beneficial owners are, in fact, affiliates of the
registrant.



The
number of shares of the registrant’s common stock outstanding as of December 24, 2015 was 38,115,356 shares.


















This
Amendment No. 2 to the Form 10-K for Petlife Pharmaceuticals, Inc. for the fiscal year ended August 31, 2015 is only filed to
correct an error in checking the inaccurate box relative to XBRL filings in the previously filed Form 10-K.











SIGNATURES



Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual
Report on Form 10-K for the fiscal year ended August 31, 2015 to be signed on its behalf by the undersigned, thereunto duly authorized.



|                    | Petlife
    Pharmaceuticals, Inc.
|------------------- | ---------------------------------
|January
    8, 2016 |                                  
|                    | By:                              
|                    |                                  
|                    |                                  
|                    |                                  
|                    | By:                              
|                    |                                  
|                    |